Full Press Release Details
DOJ Closes Investigation of
BEIJING, Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac"
or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the U.S. Department of Justice
("DOJ") has closed its investigation, with no charges, into possible violations of the Foreign Corrupt Practices Act related to
allegations that certain Sinovac employees made improper payments to Chinese government officials. The closing of the DOJ investigation
follows the SEC's termination of its related investigation, which the Company announced on August 20, 2018. With the closure
of the DOJ's investigation, the Company is not aware of any pending U.S. government investigations of the Company related to these
matters. Sinovac is committed to conducting business in compliance with all applicable laws and cooperated fully with the DOJ.
Sinovac will continue in its mission of researching, developing, manufacturing and commercializing vaccines that protect against
human infectious diseases.
Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on
the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's
product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), and mumps. Healive, the hepatitis A vaccine manufactured by the Company has passed the
assessment under WHO Prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against
hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide
to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and
stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling
program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides
vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring
growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in Asia and South
America. For more information please refer to the Company's website at www.sinovacbio.com.
Safe Harbor Statement
This announcement may include certain statements that are not descriptions of historical
facts, but are forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ materially from those contained in any such statements.
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Tel: +1-646-308-1707
Email: william.zima@icrinc.com
Tel: +1-415-745-3294
Email: sbe@abmac.com
China Media Contact:
Tel: +86-10-6583-7510
Email: Edmond.Lococo@icrinc.com